The Australian Therapeutic Goods Administration has given Vela Diagnostics approval for its Sentosa SQ HIV genotyping assay, a test that uses plasma samples from patients with HIV infection to detect HIV-1 Group M genomic mutations in reverse transcriptase, protease and integrase regions. In addition, the company's Sentosa SQ melanoma panel, which facilitates screening of 127 hot spot mutations, has been granted approval by the Singapore Health Sciences Authority for in vitro diagnostic use.
Australia, Singapore approve assays from Vela Diagnostics
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.